Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seng Gee Lim

Showing results (181-190 of 241) with videos related to

Pageof 25
Sort By:
The Journal of Clinical Investigation|January 9, 2018
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuationLaura Rivino, Nina Le Bert, Upkar S Gill, et al.
Journal of Hepatology|September 3, 2013
Reduction of HBV replication prolongs the early immunological response to IFNα therapyAnthony T Tan, Long Truong Hoang, Daniel Chin, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Management of hepatitis C virus infection in the Asia-Pacific region: an updateSeng Gee Lim, Alessio Aghemo, Pei-Jer Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
Identifying Patients With Cirrhosis Who Might Avoid Screening Endoscopy Based on Serum Albumin and Bilirubin and Platelet CountsGuan Sen Kew, Zhao Jin Chen, Alexander Wenjun Yip, et al.
Journal of Hepatology|January 8, 2016
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)Henry L Y Chan, Sang Hoon Ahn, Ting-Tsung Chang, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Hepatology (Baltimore, Md.)|January 12, 2023
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosisDaniel Q Huang, Nobuharu Tamaki, Hyung Woong Lee, et al.
The Lancet. Gastroenterology & Hepatology|July 20, 2020
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)Lai Wei, Guiqiang Wang, Negar N Alami, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2021
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCTSeng Gee Lim, Wei Lyn Yang, Jing Hieng Ngu, et al.
Journal of Virology|December 28, 2005
Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirusKuo-Ming Lip, Shuo Shen, Xiaoming Yang, et al.
Pageof 25

Showing results (181-190 of 241) with videos related to

Sort By:
Pageof 25
The Journal of Clinical Investigation|January 9, 2018
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuationLaura Rivino, Nina Le Bert, Upkar S Gill, et al.
Journal of Hepatology|September 3, 2013
Reduction of HBV replication prolongs the early immunological response to IFNα therapyAnthony T Tan, Long Truong Hoang, Daniel Chin, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Management of hepatitis C virus infection in the Asia-Pacific region: an updateSeng Gee Lim, Alessio Aghemo, Pei-Jer Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 13, 2019
Identifying Patients With Cirrhosis Who Might Avoid Screening Endoscopy Based on Serum Albumin and Bilirubin and Platelet CountsGuan Sen Kew, Zhao Jin Chen, Alexander Wenjun Yip, et al.
Journal of Hepatology|January 8, 2016
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)Henry L Y Chan, Sang Hoon Ahn, Ting-Tsung Chang, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Hepatology (Baltimore, Md.)|January 12, 2023
Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosisDaniel Q Huang, Nobuharu Tamaki, Hyung Woong Lee, et al.
The Lancet. Gastroenterology & Hepatology|July 20, 2020
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)Lai Wei, Guiqiang Wang, Negar N Alami, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2021
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCTSeng Gee Lim, Wei Lyn Yang, Jing Hieng Ngu, et al.
Journal of Virology|December 28, 2005
Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirusKuo-Ming Lip, Shuo Shen, Xiaoming Yang, et al.
Pageof 25